Home > PJ (current issue) > News / News Centre | Search

PJ Online homeThe Pharmaceutical Journal
Vol 276 No 7401 p580
20 May 2006

This article
Reprint   Photocopy

  Acrobat Reader


News summary


Lecturers’ boycott may hit pharmacy exams

Industrial action by lecturers over pay may affect the marking of pharmacy examinations at universities across the UK.

Two unions representing university lecturers — the Association of University Teachers (AUT) and NATFHE — last week turned down a final pay offer from the Universities and Colleges Employers’ Association. AUT and NATFHE members were asked to take action short of a strike, in the form of an assessment and cover boycott, earlier this year. Now the examination season has arrived, this industrial action means that examinations may be cancelled and marking delayed.

Most universities are confident that most examinations will take place as scheduled. At the schools of pharmacy contacted by The Journal industrial action has not prevented examinations from taking place although there is less certainty about whether marking of examinations will be delayed. David Packham, secretary and registrar at Aston University, told The Journal that only 10 out of 800 examinations at the university had not taken place and none of these had involved pharmacy. However, he added: “We are facing the prospect that examinations will not be marked or that staff will mark the examinations but will not release those marks.” This is a developing situation and could affect pharmacy students, he said.

The Royal Pharmaceutical Society’s education committee discussed the situation at its meeting on 4 May. Graham Phillips, chairman of the committee, said: “The Secretary and Registrar of the Royal Pharmaceutical Society has written to all universities running MPharm courses to inform them students must be assessed as agreed through the accreditation process. This means that if students are not assessed or assessed in any other way they may not be eligible to apply to enter preregistration training. Other health care regulators are considering similar action.”

Back to Top


©The Pharmaceutical Journal